NasdaqGM:PRCTMedical Equipment
PROCEPT BioRobotics (PRCT) Is Up 7.5% After Raising 2026 Revenue Outlook And Sharpening Growth Focus
In the past quarter, PROCEPT BioRobotics reported strong third-quarter 2025 execution and issued fiscal 2026 revenue expectations of US$410 million to US$430 million, while management detailed organizational changes to accelerate new account launches and boost therapy awareness.
Beyond the headline numbers, the company’s emphasis on improving procedure utilization to unlock longer-term value highlights how management is targeting deeper engagement within its existing customer base rather...

